Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 5;157:104882.
doi: 10.1016/j.phrs.2020.104882. Online ahead of print.

The Clinical Benefits of Chinese Patent Medicines Against COVID-19 Based on Current Evidence

Affiliations
Free PMC article
Review

The Clinical Benefits of Chinese Patent Medicines Against COVID-19 Based on Current Evidence

Dan Zhang et al. Pharmacol Res. .
Free PMC article

Abstract

The outbreak of emerging infectious pneumonia caused by 2019 Novel Coronavirus (2019-nCoV) has posed an enormous threat to public health, and traditional Chinese medicine (TCM) have made vast contribution to the prevention, treatment and rehabilitation of coronavirus disease 19 (COVID-19) among Chinese population. As an indispensable part of TCM, Chinese patent medicines (CPMs) are highly valued and critically acclaimed in their campaign to contain and tackle the epidemic, they can achieve considerable effects for both suspected cases under medical observation period, and confirmed individuals with serious underlying diseases or critical conditions. Given this, based on the Guideline on Diagnosis and Treatment of Coronavirus Disease 2019 in China, the present review summarized the basic information, clinical evidence and published literatures of recommended CPMs against COVID-19. The details were thoroughly introduced involving compositions, therapeutic effects, clinical indications, medication history of CPMs and the profiles of corresponding research. With regard to infected patients with different stages and syndrome, the preferable potentials and therapeutic mechanism of CPMs were addressed through the comprehensive collection of relevant literatures and on-going clinical trials. This study could provide an insight into clinical application and underlying mechanism of recommended CPMs against COVID-19, with the aim to share the Chinese experience in clinical practice and facilitate scientific development of TCM, especially CPMs in the fierce battle of COVID-19.

Keywords: COVID-19; Chinese patent medicines; Current evidence; Review.

Conflict of interest statement

Declaration of Competing Interest The authors of the manuscript that titled “The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence” declared that there are no conflicts of no financial/personal interest.

Figures

None
Fig. 1
Fig. 1
The profiles of current evidence for CPMs against COVID-19. Note: A: The retrieval results for eligible studies. B: The distribution of research types.
Fig. 2
Fig. 2
Recommended CPMs and corresponding applicable patients with COVID-19.
Fig. 3
Fig. 3
The relationship of recommended CPMs and compositions. Note: The purple nodes represented different CPMs, and compositions were labelling yellow. AGNH: Angong Niuhuang Pill; HXZQ: Huoxiang Zhengqi Capsule; JHQG: Jinhua Qinggan Granules; LHQW: Lianhua Qingwen Capsule; RDN: Reduning Injection; SF: Shenfu Injection; SFJD: Shufeng Jiedu Capsule; SHX: Suhexiang Pill; SM: Shenmai Injection; SMI: Shengmai Injection; TRQ: Tanreqing Injection; XBJ: Xuebijing Injection; XNJ: Xingnaojing Injection; XYP: Xiyanping Injection.

Similar articles

See all similar articles

References

    1. Lancet The. Emerging understandings of 2019-nCoV. Lancet. 2020;395:311. - PMC - PubMed
    1. Heymann D.L. COVID-19: what is next for public health? Lancet. 2020;395(10224):542–545. 3. - PMC - PubMed
    1. National Health Commission of the People’s Republic of China, The guideline on diagnosis and treatment of coronavirus disease 2019 (Revised 6th version). Tianjin Journal of Traditional Chinese Medicine:1–5 2020 http://kns.cnki.net/kcms/detail/12.1349.R.20200304.1638.006.html [In Chinese].
    1. Weiss P. Clinical course and mortality risk of severe COVID-19. Lancet. 2020 pii: S0140-6736(20)30633-30634.
    1. Guan W.J. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020

LinkOut - more resources

Feedback